Floatz logo

Rosiglitazone

Hyperinsulinemia

New York Medical CollegeSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

19 Active assets in the Hyperinsulinemia cohort.

Asset / SponsorPhaseRating
Metformin
Attikon Hospital
Phase 4BB
Metformin
Attikon Hospital
Phase 4BB
EUDEMINE INJECTION
Columbia University
Phase 2B
Insulin-Like Growth Factor I
Children's Hospital of Philadelphia
Phase 2B
Vigabatrin
University of Arizona
Phase 2CCC

View all 25 →

Same molecule, other indications

Rosiglitazone is also rated in:

Metabolic SyndromeDormant
BB
Indicative ·
71 / 100
View asset →
type 2 diabetes mellitusDormant
BB
Indicative ·
70 / 100
View asset →
type 2 diabetes mellitusDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →